# US Structural Heart Devices Market

> US Structural Heart Devices Market Research Report: Size, Share, Trend Analysis By Types (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) and By Procedure (Replacement Procedures, Repair Procedures) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.62%
- **2024:** $ 175.18 Million
- **2025:** $ 186.77 Million
- **2035:** $ 354.57 Million
- **Key Players:** Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US)

**Report ID:** MRFR/MED/14087-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-structural-heart-devices-market-15614

---

## Market Summary

## **US Structural Heart Devices Market Overview**

As per MRFR analysis, the US Structural Heart Devices Market Size was estimated at 173.95 (USD Million) in 2023. The US Structural Heart Devices Market Industry is expected to grow from 191.5(USD Million) in 2024 to 409.5 (USD Million) by 2035. The US Structural Heart Devices Market CAGR (growth rate) is expected to be around 7.154% during the forecast period (2025 - 2035).

### **Key US Structural Heart Devices Market Trends Highlighted**

The US Structural Heart Devices Market is witnessing significant trends driven by several factors. One important market driver is the increasing prevalence of structural heart disorders, such as valve diseases and congenital heart defects, leading to greater demand for innovative treatment solutions. The aging population in the US also plays a critical role, as older individuals are more susceptible to these conditions, prompting healthcare providers to seek effective interventions. Additionally, technological advancements in device manufacturing and minimally invasive procedures are enhancing patient outcomes, thus encouraging adoption among healthcare professionals and patients alike.

Opportunities in the US market are expanding with the growing focus on personalized medicine and enhanced patient-centered care. Companies specializing in structural heart devices are exploring partnerships with healthcare institutions to develop tailored solutions that cater to individual patient needs. This shift towards customized treatments is opening new avenues for innovation and market entry. Furthermore, an increase in clinical trials and regulatory approvals for new devices indicates a robust pipeline of upcoming products that could transform the treatment landscape for structural heart diseases.

Recently, trends in the US have also leaned towards an emphasis on remote patient monitoring and digital health solutions.The rise of telehealth, especially during the pandemic, has prompted the integration of digital technologies with structural heart devices, enabling continuous monitoring and better patient management. The growing acceptance of these technologies by both patients and healthcare providers marks a significant shift in how structural heart diseases are being treated and monitored, making the market dynamic and evolving.

As these trends continue to develop, they are likely to shape the future of the Structural Heart Devices Market in the US, influencing both product development and delivery of care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Structural Heart Devices Market Drivers**

### **Increasing Incidence of Heart Diseases**

The prevalence of heart diseases in the United States continues to rise, contributing significantly to growth in the US Structural Heart Devices Market Industry. According to the Centers for Disease Control and Prevention (CDC), about 696,000 Americans die from heart disease each year, making it the leading cause of death in the country. This alarming statistic reflects a critical need for innovative structural heart devices that can offer effective treatment options.

The American Heart Association has also reported a steady increase in heart failure cases, projecting that the number of people living with heart failure could rise to 8 million by 2030. This growing demographic creates substantial market opportunities for manufacturers and innovators in the structural heart devices field. Leading organizations such as Medtronic and Abbott have been actively advancing their portfolios to cater to this increasing demand, indicating a robust commitment to Research and Development in response to this pressing healthcare need.

### **Technological Advancements in Medical Devices**

The US Structural Heart Devices Market Industry is significantly benefitting from rapid technological advancements in medical device manufacturing. The innovation of minimally invasive devices and enhanced imaging techniques have transformed surgical procedures. For example, transcatheter aortic valve replacement (TAVR) procedures have grown substantially, with the Society for Cardiovascular Angiography and Interventions noting a 24% increase in TAVR procedures performed in hospitals across the US.

These advancements not only improve patient outcomes by reducing recovery times and hospital stays but also attract healthcare providers towards newer technologies. Companies like Edwards Lifesciences are at the forefront of these innovations, continuously developing devices that integrate advanced materials and designs, contributing to the overall growth and efficacy of the US Structural Heart Devices Market.

### **Growing Geriatric Population**

The aging population in the United States is poised to drive significant growth in the US Structural Heart Devices Market Industry. According to the Administration for Community Living, the number of individuals aged 65 and older is expected to double from 52 million in 2018 to more than 95 million by 2060. This demographic shift leads to increased incidences of age-related illnesses, including heart valve diseases, pushing the demand for structural heart devices.

This trend encourages healthcare providers and device manufacturers to focus on products tailored for elderly patients, enhancing treatment efficacy and safety. Companies like Boston Scientific are aligning their product strategies to address the specific needs of this growing patient segment, further propelling market growth and technological advancements.

## **US Structural Heart Devices Market Segment Insights**

### **Structural Heart Devices Market Type Insights**

The US Structural Heart Devices Market, categorized by Type, showcases a progressive landscape that is essential for addressing various cardiovascular conditions affecting patients across the region. The Heart Valve Devices segment plays a critical role in this market, as it is specifically designed for the treatment of valvular heart diseases, which are prevalent among the aging population in the United States. With a growing emphasis on minimizing risks associated with surgeries, these devices often adopt less invasive techniques, thus driving their acceptance and adoption among medical professionals.

Meanwhile, Annuloplasty Rings are instrumental in supporting effective mitral and tricuspid valve repair procedures. They possess a significant impact on enhancing post-surgical recovery outcomes, thereby contributing positively to the overall operational efficiency within hospitals. Occluders are another vital component of the Type classification, primarily addressing issues related to congenital heart defects. By efficiently sealing abnormal holes in the heart, these devices decrease complications and improve the quality of life for affected patients.

Their increasingly favorable acceptance stems from advancements in device technology and better patient outcomes, which are important metrics for healthcare providers. Additionally, Delivery Systems ensure the accurate placement of these cardiac devices within the heart, which is crucial for ensuring effectiveness. As technology evolves, the precision and reliability of Delivery Systems have notably improved, allowing for more successful procedures and better patient satisfaction.

Throughout the industry, the focus on enhancing patient outcomes, paired with an increasing prevalence of cardiovascular diseases, are strong growth drivers for all Types of devices within the US Structural Heart Devices Market. Furthermore, the rising trend of minimally invasive surgeries is pushing innovation in device designs and delivery methods, as healthcare providers strive for safer and more efficient solutions. Challenges remain, including regulatory hurdles and the need for substantial Research and Development investments before new devices can reach the market, but the overall opportunities for growth within this segment are significant.

The increasing demand for heart-related interventions presents a favorable environment for manufacturers and healthcare providers alike, fostering advancements that align with the ongoing evolution of cardiovascular care in the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Structural Heart Devices Market Indication Insights**

The US [Structural Heart Devices](../../../reports/structural-heart-devices-market-6385) Market is significantly influenced by the indication segment, where conditions such as Valvular Heart Disease and Cardiomyopathy play crucial roles. Valvular Heart Disease often necessitates intervention through devices such as transcatheter aortic valves or repair devices, addressing a critical need for many patients suffering from debilitating symptoms. Cardiomyopathy, on the other hand, represents a diverse range of heart muscle diseases, also driving the adoption of structural heart devices to improve quality of life and manage symptoms effectively.

The rising prevalence of these conditions in the US, and the increasing awareness of available treatment options, support robust growth within this market. Technological advancements in device design and implementation further enhance procedural success rates, thereby contributing to the positive outlook of the US Structural Heart Devices Market industry. Furthermore, the aging population in the US, which is more susceptible to heart diseases, presents ample opportunities for market expansion and advancements in this therapeutic area. Overall, the attention given to these indications underscores the importance of structural heart interventions in contemporary cardiovascular care.

### **Structural Heart Devices Market Procedure Insights**

The US Structural Heart Devices Market is experiencing significant advancements within the Procedure segment, particularly highlighted by the growing focus on Replacement Procedures and Repair Procedures. Replacement Procedures are crucial as they address severe heart valve diseases, providing life-saving options for patients who may otherwise face severe health risks. On the other hand, Repair Procedures have gained favor due to their less invasive nature, often resulting in quicker recovery times and fewer complications.

These procedures play a vital role in managing conditions such as valve stenosis and regurgitation, showcasing the importance of intervention in preventing further cardiovascular complications. The rising incidence of heart diseases in the US is driving the demand within this segment, with healthcare professionals increasingly emphasizing the benefits of early intervention. Moreover, technological advancements and innovation within the US medical device industry are further enhancing the effectiveness of these procedures.

As a result, the Procedure segment is poised to play a significant role in transforming patient outcomes and driving procedural volume in the years to come, indicating a promising trajectory for the US Structural Heart Devices Market.

## **US Structural Heart Devices Market Key Players and Competitive Insights**

The US Structural Heart Devices Market has become a crucial area within the broader cardiovascular sphere, primarily driven by the increasing prevalence of heart diseases and the population's aging demographic. Technological innovations, a rise in minimally invasive procedures, and heightened awareness of heart health are propelling this market into a competitive landscape characterized by rapid advancements and strategic collaborations. Companies operating in this segment focus on enhancing procedural efficiencies and improving patient outcomes, leading to an influx of novel devices that cater to various structural heart conditions.

Market players continually seek to strengthen their foothold by investing in research and development, aligning with healthcare providers, and exploring new therapeutic avenues, all of which underline the importance of competitive insights in navigating this dynamic sector.

LivaNova stands out in the US Structural Heart Devices Market due to its commitment to advancing patient care through innovative devices and therapies. The company’s focus on providing cutting-edge products, along with a strong emphasis on research, plays a significant role in its sustained market presence. LivaNova has successfully developed technologies that address various structural heart-related ailments, thereby enhancing treatment options for healthcare providers. The integration of clinical data and patient feedback into the product development cycle allows LivaNova to retain a competitive edge, ensuring their offerings are aligned with real-world needs.

The company’s robust partnerships and collaborations with hospitals and cardiovascular specialists in the US reinforce its commitment to improve procedural success and are pivotal in bolstering its reputation within the marketplace.

AtriCure operates with a distinctive approach in the US Structural Heart Devices Market, primarily focusing on innovative solutions for atrial fibrillation and other structural heart conditions. The company offers a range of products, particularly in ablation technologies that target the correction of irregular heartbeats associated with various structural heart diseases. AtriCure has made notable advancements in its product portfolio, emphasizing minimally invasive techniques that allow for improved recovery times and reduced patient risk. Their strategic mergers and acquisitions have enabled AtriCure to broaden its technological capabilities and expand its market share.

By leveraging these strengths, the company has established a solid foundation in the US market, consistently prioritizing research and enhancing collaborations with healthcare providers to drive forward the development of advanced therapies. The synergy from these efforts continues to bolster AtriCure’s position in the competitive landscape, offering innovative solutions that cater specifically to the evolving needs of patients and healthcare systems.

### **Key Companies in the US Structural Heart Devices Market Include**

## **US Structural Heart Devices Market Industry Developments**

Recent developments in the US Structural Heart Devices Market have included significant advancements and investments as companies focus on innovative therapies. Notably, Medtronic has gained attention with its ongoing investment in the HeartWare product line designed for heart failure treatments. Abbott Laboratories continues to expand the adoption of its MitraClip device, which has shown substantial success in treating mitral valve regurgitation. In September 2023, Boston Scientific made headlines with a strategic partnership aimed at enhancing its structural heart portfolio, further solidifying its place in the market.

Acquisitions have also been influential in the market landscape, such as Edwards Lifesciences acquiring a technology firm in June 2023 to accelerate its Research and Development efforts for transcatheter heart valves. Additionally, in the same month, LivaNova announced its merger with a leading cardiovascular technology organization, strengthening its market position and enhancing its product offerings.

The growth in market valuations among key players reflects an overall expanding interest in structural heart therapies, with the total market value anticipated to surpass USD 12 billion by 2025 as more patients are diagnosed and treated, emphasizing the importance of alliances and innovation in this sector.

## **US Structural Heart Devices Market Segmentation Insights**

### **Structural Heart Devices Market Type Outlook**

### **Structural Heart Devices Market Indication Outlook**

### **Structural Heart Devices Market Procedure Outlook**

## Market Drivers

### Supportive Reimbursement Policies

Supportive reimbursement policies in the US are playing a pivotal role in the growth of the structural heart-devices market. Insurance providers are increasingly recognizing the value of advanced structural heart devices and are offering favorable reimbursement rates for these procedures. This trend is encouraging healthcare providers to adopt innovative technologies, as the financial burden on patients is reduced. Additionally, government programs and initiatives aimed at improving access to cardiac care are further bolstering the market. As reimbursement policies evolve to support the use of advanced devices, the structural heart-devices market is expected to expand, providing patients with greater access to life-saving treatments and improving overall health outcomes.

### Technological Innovations in Device Design

Technological innovations in the design and functionality of structural heart devices are transforming the market landscape. Advances in materials science, imaging technologies, and minimally invasive techniques are enabling the development of more effective and safer devices. For instance, the introduction of bioresorbable stents and transcatheter heart valves has revolutionized treatment options for patients with structural heart conditions. These innovations not only enhance patient outcomes but also reduce recovery times and hospital stays, making them attractive options for both patients and healthcare providers. As manufacturers continue to invest in research and development, the structural heart-devices market is likely to witness a surge in new product launches and improved device performance, further driving market growth.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases in the US is a primary driver for the structural heart-devices market. According to the American Heart Association, cardiovascular diseases account for approximately 1 in every 4 deaths in the US. This alarming statistic highlights the urgent need for effective treatment options, including structural heart devices. As the population ages and lifestyle-related health issues become more prevalent, the demand for innovative solutions to manage these conditions is expected to rise. The structural heart-devices market is likely to benefit from this trend, as healthcare providers seek advanced technologies to improve patient outcomes and reduce healthcare costs. Furthermore, The market is projected to grow at a CAGR of around 8% from 2025 to 2035.

### Growing Awareness and Education on Heart Health

The rising awareness and education regarding heart health among the US population is a crucial driver for the structural heart-devices market. Public health campaigns and initiatives aimed at educating individuals about cardiovascular diseases and their risk factors have led to increased screening and early diagnosis. As more people become aware of their heart health, there is a greater likelihood of seeking medical intervention, which includes the use of structural heart devices. This heightened awareness is expected to contribute to the growth of the market, as patients are more inclined to explore treatment options. Furthermore, healthcare providers are increasingly emphasizing the importance of preventive care, which may lead to earlier interventions and a higher demand for innovative devices in the structural heart-devices market.

### Increased Investment in Healthcare Infrastructure

Investment in healthcare infrastructure in the US is significantly impacting the structural heart-devices market. With the ongoing expansion of hospitals and specialized cardiac care centers, there is a growing demand for advanced medical technologies. The US government and private sector are allocating substantial funds to enhance healthcare facilities, which includes the procurement of state-of-the-art structural heart devices. This trend is expected to create a favorable environment for manufacturers and suppliers in the structural heart-devices market. As healthcare facilities upgrade their equipment and technology, the adoption of innovative devices is likely to increase, thereby driving market growth. Additionally, the focus on improving patient care and outcomes is pushing healthcare providers to invest in advanced solutions, further propelling the demand for structural heart devices.

## Future Outlook

The [Structural Heart Devices Market](https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385) structural heart-devices market is projected to grow at a 6.62% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

**New opportunities:**

- Development of minimally invasive surgical techniques for device implantation. Expansion of telehealth services for remote patient monitoring and follow-up. Investment in AI-driven analytics for personalized treatment plans and device optimization.

By 2035, the market is expected to achieve substantial growth, driven by innovation and increasing demand.

## Segment Insights

### By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing)

The US structural heart-devices market exhibits distinct segmentation, with Transcatheter Aortic Valve Replacement (TAVR) holding the largest share among the available device types. This segment has gained significant traction due to its minimally invasive nature and favorable outcomes compared to traditional surgical options. In contrast, Mitral Valve Repair Devices are swiftly gaining market share as healthcare providers increasingly adopt innovative solutions for mitral valve conditions, driven by growing awareness and successful clinical outcomes. Growth trends indicate a robust increase in demand for both TAVR and Mitral Valve Repair Devices. Factors contributing to this growth include rising incidences of heart diseases, advancements in medical technology, and an aging population more prone to structural heart issues. Furthermore, as healthcare systems prioritize less invasive procedures, the market for Left Atrial Appendage Closure Devices and Transcatheter Pulmonary Valve is also expanding, although at a slower rate compared to TAVR and Mitral Valve Repair Devices.

Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging)

Transcatheter Aortic Valve Replacement (TAVR) is the dominant player in the structural heart-devices segment, primarily due to its established safety profile and effectiveness in patients with severe aortic stenosis. The procedure's minimally invasive approach significantly reduces recovery time, making it preferable for older patients who may not tolerate traditional surgery well. On the other hand, Mitral Valve Repair Devices, although emerging, are capturing attention with innovative technologies that offer effective solutions for mitral regurgitation. These devices are gaining traction due to their efficacy and the rising demand for less invasive surgical alternatives. As research and development efforts continue, we can expect further advancements in this class of devices, leading to enhanced clinical outcomes and increasing adoption rates.

### By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing)

In the US structural heart-devices market, the procedure type segment reveals that minimally invasive techniques dominate the landscape due to their advantages in reducing recovery time and hospital stays. Surgical procedures, while traditionally significant, have seen a gradual shift as advancements in technology enhance the efficacy of less invasive options, capturing a notable share of the market. Growth trends indicate a strong inclination toward percutaneous and minimally invasive methods, driven by increasing patient awareness and preference for less traumatic solutions. The surgical segment, however, is witnessing a resurgence as innovative techniques and technologies emerge, making it the fastest-growing option. This evolution underscores the dynamic nature of the market and the continuous need for adaptation by manufacturers.

Minimally Invasive (Dominant) vs. Surgical (Emerging)

Minimally invasive procedures are characterized by their ability to significantly reduce risk, pain, and recovery time, positioning them as the dominant force in the market. The appeal lies in their precision and efficiency, catering to a growing segment of health-conscious patients seeking effective treatments with minimal impact. On the other hand, surgical techniques, once the gold standard, are now emerging with new technology that bridges the gap created by minimally invasive alternatives. These advances are enabling surgical procedures to regain traction, catering to complex cases where minimally invasive approaches may not suffice. As such, the market reflects a diverse range of preferences, with both methodologies playing crucial roles in patient care.

### By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing)

In the US structural heart-devices market, Aortic Stenosis holds the largest share among the indication segments, driven by an increasing patient population and a high prevalence of the condition. Mitral Regurgitation is emerging as a rapidly growing segment, with advancements in treatment options contributing to its market growth. Heart Failure and Pulmonary Valve Stenosis, while important, currently represent smaller shares in comparison to these dominant segments. The growth of the Mitral Regurgitation segment is attributed to the rise in minimally invasive procedures and improved device technology, which enhances patient outcomes. Factors such as an aging population and increasing awareness about heart diseases are stimulating demand across the segments. As healthcare providers embrace innovative treatments, both Aortic Stenosis and Mitral Regurgitation segments are expected to see sustained growth in the near future.

Aortic Stenosis (Dominant) vs. Mitral Regurgitation (Emerging)

Aortic Stenosis is characterized by the narrowing of the aortic valve, leading to significant cardiac complications. This segment benefits from established treatment protocols and a strong market presence, making it the dominant force within the indications. Conversely, Mitral Regurgitation is gaining traction, driven by innovative therapies and a growing recognition of the condition's impact on heart health. This segment is increasingly seen as an emerging opportunity, particularly with the introduction of cutting-edge devices and techniques, which are proving effective in addressing the condition. As both segments evolve, they will likely shape the future landscape of the US structural heart-devices market.

### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the US structural heart-devices market, hospitals command a significant share, reflecting their pivotal role in providing advanced cardiovascular care. They are equipped with the latest technologies and specialized staff, making them a primary destination for complex procedures. In contrast, ambulatory surgical centers are rapidly increasing their market presence, capitalizing on the demand for cost-effective and efficient outpatient care. This trend is driven by the growing preference for less invasive procedures that can be completed in a single visit without the need for prolonged hospital stays. Growth trends reveal that while hospitals remain the dominant end-user segment, ambulatory surgical centers are poised for substantial growth. Factors contributing to this shift include changes in reimbursement models favoring outpatient procedures, technological advancements that enable safe and efficient surgeries outside traditional hospital settings, and patients' increasing desire for convenience. Additionally, cardiology clinics are also witnessing steady demand, providing a tailored approach to heart care for specific patient needs.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals play a dominant role in the US structural heart-devices market, characterized by their comprehensive facilities and ability to handle complex cases that require extensive surgical intervention and critical care. Their robust infrastructure supports a wide range of procedures, establishing them as trusted centers for cardiovascular treatments. On the other hand, ambulatory surgical centers are increasingly seen as an emerging segment, offering a streamlined approach to less complex heart procedures. These centers provide patients with quick access to care, lower costs, and a focus on minimally invasive techniques. As patients opt for faster recovery times and reduced overall expenses, the appeal of ambulatory surgical centers continues to grow, positioning them as a competitive alternative to traditional hospital settings.

## Competitive Benchmarking

The structural heart-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of heart diseases. Key players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Edwards Lifesciences (US) focuses on innovation, particularly in transcatheter heart valves, while Medtronic (US) emphasizes a broad portfolio that includes both surgical and minimally invasive solutions. Abbott Laboratories (US) is leveraging partnerships to expand its product offerings, particularly in the realm of left atrial appendage closure devices. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and patient-centric solutions. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set trends in product development and market strategies that smaller firms often follow. In October 2025, Edwards Lifesciences (US) announced the launch of its latest transcatheter aortic valve replacement (TAVR) system, which incorporates advanced imaging technology to improve procedural outcomes. This strategic move is significant as it not only reinforces Edwards' commitment to innovation but also positions the company to capture a larger share of the growing TAVR market, which is expected to expand due to increasing patient demand. In September 2025, Medtronic (US) revealed a partnership with a leading telehealth provider to integrate remote monitoring capabilities into its heart devices. This initiative is crucial as it aligns with the ongoing trend towards digital health solutions, enabling better patient management and potentially improving clinical outcomes. Such collaborations may enhance Medtronic's competitive edge by offering comprehensive solutions that address both device performance and patient care. In August 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in the US to meet the rising demand for its heart devices. This expansion is indicative of Abbott's strategy to ensure supply chain reliability and responsiveness, which is increasingly vital in a market where timely access to innovative products can significantly influence patient outcomes. By bolstering its production capacity, Abbott positions itself to better serve healthcare providers and patients alike. As of November 2025, current trends in the structural heart-devices market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in device development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and market reach. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability rather than solely on price. This shift suggests that companies that prioritize innovation and patient-centric solutions will be better positioned to thrive in an increasingly competitive landscape.

## Recent News & Developments

Recent developments in the US Structural Heart Devices Market have included significant advancements and investments as companies focus on innovative therapies. Notably, Medtronic has gained attention with its ongoing investment in the HeartWare product line designed for heart failure treatments. Abbott Laboratories continues to expand the adoption of its MitraClip device, which has shown substantial success in treating mitral valve regurgitation. In September 2023, Boston Scientific made headlines with a strategic partnership aimed at enhancing its structural heart portfolio, further solidifying its place in the market.

Acquisitions have also been influential in the market landscape, such as Edwards Lifesciences acquiring a technology firm in June 2023 to accelerate its Research and Development efforts for transcatheter heart valves. Additionally, in the same month, LivaNova announced its merger with a leading cardiovascular technology organization, strengthening its market position and enhancing its product offerings.

The growth in market valuations among key players reflects an overall expanding interest in structural heart therapies, with the total market value anticipated to surpass USD 12 billion by 2025 as more patients are diagnosed and treated, emphasizing the importance of alliances and innovation in this sector.

## Report Scope

| MARKET SIZE 2024 | 175.18(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 186.77(USD Million) |
| MARKET SIZE 2035 | 354.57(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.62% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US) |
| Segments Covered | Type, Procedure Type, Indication, End User |
| Key Market Opportunities | Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the structural heart-devices market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US structural heart-devices market?**
A: The market valuation was $175.18 Million in 2024.

**Q: What is the projected market size for the US structural heart-devices market by 2035?**
A: The market is projected to reach $354.57 Million by 2035.

**Q: What is the expected CAGR for the US structural heart-devices market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.62% from 2025 to 2035.

**Q: Which companies are the key players in the US structural heart-devices market?**
A: Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, and Boston Scientific.

**Q: What are the main segments of the US structural heart-devices market?**
A: The main segments include Type, Procedure Type, Indication, and End User.

**Q: What was the valuation of Transcatheter Aortic Valve Replacement in 2024?**
A: The valuation for Transcatheter Aortic Valve Replacement was $70.0 Million to $140.0 Million in 2024.

**Q: How much is the Mitral Valve Repair Devices segment expected to grow by 2035?**
A: The Mitral Valve Repair Devices segment is expected to grow from $50.0 Million to $100.0 Million by 2035.

**Q: What is the projected valuation for Left Atrial Appendage Closure Devices by 2035?**
A: The projected valuation for Left Atrial Appendage Closure Devices is $30.0 Million to $70.0 Million by 2035.

**Q: Which end user segment had the highest valuation in 2024?**
A: In 2024, the Hospitals segment had the highest valuation at $70.0 Million to $140.0 Million.

**Q: What is the expected growth for the Pulmonary Valve Stenosis indication by 2035?**
A: The Pulmonary Valve Stenosis indication is expected to grow from $45.18 Million to $94.57 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-structural-heart-devices-market-15614*